Tumor-specific MHC-II expression predicts response to atezolizumab combined to chemotherapy
By analyzing data from the NeoTRIP trial, tumor-specific MHC-II expression was validated as a biomarker associated with improved response to neoadjuvant chemo-immunotherapy in early triple negative breast cancer